Latest Continuous Disclosure News

Insignia Financial has revealed ongoing discussions with CC Capital Partners regarding a revised acquisition proposal, with a binding offer expected soon but no guarantee of a deal.

Collins Foods Limited has confirmed its FY25 earnings aligned closely with market forecasts, addressing ASX concerns over potential surprises. The company highlighted positive margin outcomes and clarified the impact of a Netherlands impairment.

Santos Limited has entered a process deed granting XRG Consortium exclusive rights to pursue a potential A$8.89 per share cash takeover offer, setting the stage for a pivotal chapter in the oil and gas sector.

Range International’s Indonesian subsidiary has successfully overturned 2018 tax assessments, eliminating a significant financial burden and clearing the way for focused growth.

Locate Technologies Limited has responded to an ASX inquiry about unusual trading activity, confirming no undisclosed information and compliance with listing rules. The company points to recent capital raising announcements as context for the share price movement.

EML Payments has reached an in-principle agreement to settle a $37.36 million shareholder class action related to its 2020 acquisition, allowing the company to focus on its strategic growth plans.

Solis Minerals has voluntarily delisted from the TSX Venture Exchange to concentrate on its primary ASX listing, prompting changes to its ASX waivers and financial reporting calendar.

BlinkLab Limited has responded to an ASX query regarding recent unusual trading activity, confirming no undisclosed material information exists and highlighting pending ADHD diagnostic results expected later this year.

archTIS Limited addresses ASX concerns over a sharp rise in its share price, linking the movement to recent contract wins in major defence markets and ongoing acquisition talks in the US.

New World Resources has increased its scheme offer to 5.5 cents per share, while rival Kinterra proposes a higher 5.7 cents off-market takeover bid. The board is reviewing the competing offers amid uncertainty over the final outcome.

INOVIQ Limited has responded to ASX queries defending its announcement that its new CAR-NK-EV treatment killed 88% of breast and lung cancer cells in vitro, confirming compliance with disclosure rules and providing detailed study data.

Provaris Energy has responded to ASX inquiries following a notable surge in its share price and trading volume, denying any undisclosed material information while confirming engagement of a lead manager for a potential capital raising.